Neurology Journal, 31 Jul 2024 This study provides Class III evidence that terazosin, doxazosin, and alfuzosin use reduces the rate of developing dementia…
Neurology Journal, 30 Jul 2024 This study provides Class III evidence that terazosin, doxazosin, and alfuzosin use reduces the rate of developing dementia…